University of North Carolina Medical Center

Chapel Hill, North Carolina 27599-7305

10 studies enrolling now · 53 studies all time

What they study most

Active Nonsegmental Vitiligo, Acute Coronary Syndrome, Alopecia Areata, Alpha 1-Antitrypsin Deficiency, Alpha1-Antitrypsin Deficiency, Atrial Fibrillation, Biopsy-proven, Positive Lymph Node(s), Brain Injuries, Traumatic, Breast Cancer, Breast Cancer Screening, Breast Neoplasms, COVID-19

Studies at this site

• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) — Recruiting now
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin — Recruiting now
• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer — Recruiting now
• Telerehabilitation In The Home After Stroke — Recruiting now
• A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis — Recruiting now
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now
• Preventing Suicidal Behavior With Diverse High-Risk Youth in Acute Care Settings — Recruiting now
• Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) — Recruiting now
• Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma — Recruiting now
• Anticoagulation in ICH Survivors for Stroke Prevention and Recovery — Recruiting now
• EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease — Recruiting now
• A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity — Running, not enrolling
• A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer — Running, not enrolling
• Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) — Running, not enrolling
• Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) — Running, not enrolling
• Advanced Robotic Techniques and Rapid Onsite Evaluation for Minimally Invasive Diagnosis and Next-Generation Sequencing. — Starting soon
• A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) — Running, not enrolling
• Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease — Running, not enrolling
• A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata — Running, not enrolling
• A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) — Completed
• Brain Oxygen Optimization in Severe TBI, Phase 3 — Running, not enrolling
• A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes — Running, not enrolling
• A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk — Completed
• A Study of Ponsegromab in People With Heart Failure — Stopped early
• A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo — Completed
• A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight — Running, not enrolling
• A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) — Stopped early
• A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes — Withdrawn before enrolling
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight — Completed
• Multicenter ACL Revision Study (MARS) — Running, not enrolling
• Novel Experimental COVID-19 Therapies Affecting Host Response — Completed
• Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation — Running, not enrolling
• Using Point-of-Care-Ultrasound (POCUS) to Assess Gastric Contents Among Fasting Pre-operative Patients Taking GLP-1 Agonists. — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss — Completed
• A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight — Completed
• Trial of a Mammography Decision Aid for Women Aged 75 and Older — Completed
• Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype — Completed
• Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype — Stopped early
• A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies. — Withdrawn before enrolling
• Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients — Completed
• All in One Study: A Prospective Trial of Electromagnetic Navigation for Biopsy of Pulmonary Nodules — Completed
• Fibroid Growth Study — Completed
• High-Dose Deferoxamine in Intracerebral Hemorrhage — Stopped early
• Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial — Completed
• Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation — Completed
• Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension — Completed
• NIEHS/UNC Environmental Polymorphism Study — Completed